Of the three factors that affect sex-based differences in metabolism, panelist Yong Xu, MD, PhD, said the most obvious is gonadal hormones, testosterone and estradiol, and their receptor signaling. The most fundamental factor is sex-linked chromosomes, and the most ignored is autosomal genes, he explained. Read more

Research with humans, other primates, and fruit flies has revealed new understanding of how when food is consumed and other factors affect metabolism. Early time-restricted feeding may be a strategy for the improvement of cardiovascular risk in older populations, Kylie Kavanagh, DVM, MS, MPH, reported. Read more

Growing recognition of the impact of hypertension on maternal and fetal outcomes has helped drive recent changes to lower treatment targets for the condition during pregnancy. Kartik K. Venkatesh, MD, PhD, discussed the latest updates in hypertension in pregnancy. The dynamics of hypertriglyceridemia and pregnancy, and breastfeeding and cardiometabolic health also were discussed. Read more

Diabetes-related retinal disease is prevalent in adults with diabetes and the most common cause of blindness in working-age adults. Current therapies target interventions during the late stages of retinal disease, when vision is already dramatically compromised. Jennifer Sun, MD, MPH, Stela Vujosevic, MD, PhD, and Patrice E. Fort, MS, PhD, discussed potential solutions for patients to preserve vision and prevent retinal disease progression. Read more

The promise of treatment informed by patient genetics continues to grow for people living with monogenic diabetes, type 1 diabetes, type 2 diabetes, and gestational diabetes. One ongoing barrier in the U.S. is lack of insurance coverage for genetic testing, said Rochelle N. Naylor, MD, part of a panel on the international Precision Medicine in Diabetes Initiative. Read more

Designers and engineers play a role in the effectiveness and usability of diabetes technology, and three experts, including Wendy Rogers, PhD, gathered for a panel discussion about quality teams and what they can learn from design and engineering processes. Dr. Rogers outlined a framework for designing technology that supports patients from diagnosis to sustained self-care. Read more

The microbiome accounts for 99% of the genes in a human, yet the notion that the microbiome plays a role in human obesity is all hype, according to Max Nieuwdorp, MD, PhD. He debated Rob Knight, PhD, on this issue. Dr. Knight supported the argument that the microbiome is key in obesity. Read more

James D. Johnson, PhD, and Kevin D. Hall, PhD, discussed the scientific merit of and the hypotheses driving the two leading models for understanding obesity: the carbohydrate-insulin model and the energy-balance model. Read more

In the U.S. alone, the direct cost of hospitalization for severe hypoglycemia tops $1.8 billion, reported Alexandria Ratzki-Leewing, PhD, in a session that offered a detailed look at the challenges hypoglycemia causes for older people living with diabetes, including health outcomes and financial burdens. Read more

Following the COVID-19 pandemic, researchers observed an increase in type 2 diabetes among adolescents. Experts, including Katie O’Sullivan, MD, presented three strategies to help address the disease in youths: mobilize an interdisciplinary team, explore medical or surgical treatments, and provide community intervention programs. Read more

The debate continues over using beta-cell replacement or automated insulin delivery in the treatment of patients with type 1 diabetes. Michael R. Rickels, MD, MS, presented support for the biological solution provided by islet transplantation, while Bruce A. Buckingham, MD, presented data supporting the artificial pancreas. Read more

Michael Riddell, PhD, and Lori M. Laffel, MD, MPH, provided insight into the unique needs of athletes—children and adults—who live with type 1 diabetes. Different forms of exercise affect glycemia differently, making it important for the type, duration, and intensity of exercise to be factored into the athlete’s care plan. Read more

Growing evidence indicates SGLT2 inhibitors and GLP-1 receptor agonists have beneficial effects not only in patients with type 2 diabetes but also those at risk for cardiovascular disease. Physicians and scientists, including Darren K. McGuire, MD, MHSc, presented findings from trials that demonstrate positive clinical outcomes. Read more

Cancer immunotherapy, monogenic primary immune deficiencies, and celiac disease may have pathologic links to type 1 diabetes. Four experts, including Arabella Young, PhD, discussed ways these conditions may be linked, and in some cases how they can be screened for together. Read more

More than 3 million Americans use continuous glucose monitoring, which provides a plethora of useful data for clinicians. Obtaining and interpreting that data continues to present challenges. Rebecca Rick Longo, MSN, ACNP-BC, CDCES, offered solutions for efficiently downloading the data, and Cari Berget, MPH, RN, CDCES, explained a three-step process for reviewing and using the data to support clinical decision-making. Read more

Before DCCT/EDIC, most individuals with type 1 diabetes died in their late 40s. Four decades later, David M. Nathan, MD, Chair of the DCCT/EDIC Research Group, and other investigators explained how management of the disease has been transformed by the data gleaned from this groundbreaking research and, as a result, lifespans have been extended. Read more

New statistics indicate that more than 1.31 billion people across the globe could be living with diabetes in the next 30 years. In a special symposium on how inequity contributes to the significant growth in this population, Louise J. Maple-Brown, MBBS, FRACP, PhD, and Sian Graham, BAppSc, discussed how select social determinants of health impact diabetes outcomes. Read more

Ralph A. DeFronzo, MD, and David M. Nathan, MD, debated whether combination therapy or sequential therapy is the most effective regimen for treating type 2 diabetes. Dr. DeFronzo advocated for combination therapy for its ability to efficiently correct multiple pathophysiologic defects. Dr. Nathan countered that sequential therapy is a more verifiable and efficient initial approach to disease management. Read more

The COORDINATE-Diabetes trial studied the impact of a multifaceted educational intervention for clinical staff on prescription rates for three groups of therapies used to treat type 2 diabetes and cardiovascular disease. “COORDINATE shows that it is possible to change prescribing behavior using a process that is not resource intensive,” said Principal Investigator Christopher B. Granger, MD, FACC, FAHA. Read more

Researchers presented results from their studies of the effects of retatrutide on obesity, type 2 diabetes, and nonalcoholic steatohepatitis. “The most interesting reason to pursue glucagon agonism in a multi-receptor agonist is the possibility that you could alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia,” said David A. D’Alessio, MD. Read more

A panel of investigators shared conclusions from two clinical trials studying the efficacy of oral semaglutide in treating diabetes and obesity. “The availability of an oral GLP-1 with weight-lowering efficacy could potentially give people requiring treatment for obesity and their physicians a great option for choice of treatment,” said Julio Rosenstock, MD. Read more

ARMMS-T2D showed gastric bypass, sleeve gastrectomy, and adjustable gastric band surgeries to be more effective than intensive medical and lifestyle management for individuals with type 2 diabetes. Anita Courcoulas, MD, MPH, shared results from the prospective, observational follow-up to four trials comparing surgery and medical management. Read more

Experts including cardiologist Heather M. Johnson, MD, MS, MMM, analyzed the association of hyperlipidemia, hypertension, and glucose levels with macrovascular risk at the 83rd Scientific Sessions. Their discussion focused on a case study of a patient with diabetes and hypertension to determine the best treatment to manage both. Read more

DKD may look the same clinically in type 1 diabetes and type 2 diabetes, but research suggests there are differences that could influence risk, progression, and treatment for patients with each type of diabetes. “We are looking into molecular pathways and planning direct comparisons between type 1 diabetes and type 2 diabetes to find altered mechanisms,” said Viji Nair, PhD, MS. Read more

Factors including food insecurity, community, and economic disadvantage play integral roles in the development and care of diabetes, according to four experts who took a closer look at social determinants of health and diabetes. Felicia Hill-Briggs, PhD, ABPP, provided an overview of SDOH in the development of diabetes. She was the chair of the committee that wrote the scientific review of SDOH for Diabetes Care. Read more

Nutrient-stimulated hormones have changed the landscape of weight loss recently, and four scientists, including Jonathan Campbell, PhD, presented information about several types of combinations of these therapies that have and are being tested in trials. Read more

In a Monday morning symposium, three scientists spotlighted major advancements in diabetes from the past year, from new guidelines and statements to a bionic pancreas and anti-obesity drugs. John B. Buse, MD, PhD, reported that health equity issues remain the biggest challenge in advancing diabetes treatment and prevention. Read more

Nutrition plays a significant role in a patient’s diabetes management, but there is no universal approach to incorporating a healthy diet. Ka Hei Karen Lau, MS, RDN, LDN, CDCES, and other specialists explored various nutrition programs, such as providing food benefits to those without access to food, offering education on food choices, and addressing weight stigma. Read more

Alka M. Kanaya, MD, shared clinical implications from her research, Mediators of Atherosclerosis in South Asians Living in America, which aims to understand the factors that lead to diabetes in South Asian populations. South Asian individuals in the U.S. have the highest prevalence of diabetes compared to other racial or ethnic groups. Read more

The work of physician-scientist Matthias H. Tschöp, MD, has transformed the fight against obesity and diabetes. As the Banting Medal for Scientific Achievement honoree, he shared insights into the ongoing quest to reverse obesity, including the possibilities offered by the approval of tirzepatide for the treatment of type 2 diabetes. Read more

Studies harness real-world data for vital insights into patient populations and can help determine the delivery of care for patients with diabetes. Experts, including Kristi Reynolds, PhD, MPH, FAHA, FACE, discussed the utility of real-world data and how having access to electronic health records can help in examining long-term trends. Read more

Guidelines and standards of care are helpful for many, but some populations require a more individualized approach to diabetes care. Experts, including Rodolfo J. Galindo, MD, shared the tools they’ve made available to patients who may need alternative ways to monitor and self-manage their diabetes. Read more

Data continue to provide strong evidence favoring metabolic surgery to other treatment options for type 2 diabetes remission. Principal Investigator John Kirwan, MSc, PhD, will present ARMMS-T2D study results comparing surgery versus medical and lifestyle intervention in patients with the disease, as well as long-term effects post-surgery. Read more

Experts in diabetes and eye health will discuss how the therapies used in the treatment of diabetes relate to the development and progression of diabetic retinopathy. Risa Wolf, MD, will share data that suggests GLP-1 receptor agonists can worsen diabetic retinopathy. Read more

Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are making an impact in treating patients with type 2 diabetes who may be at high risk for atherosclerotic cardiovascular disease and heart failure. Darren K. McGuire, MD, MHSc, will review both classes of drugs as part of an expert panel. Read more

As treatments for diabetic kidney disease evolve, a panel of diabetes care experts will discuss what is happening in the world of antihyperglycemic and antihypertensive agents—and beyond—as the disease continues to be a prevalent complication from diabetes. Christine Limonte, MD, will discuss whether diabetes care professionals are following guidelines in using new therapies. Read more

Michael Sefton, ScD, and a collaborative panel of experts will discuss cell therapy and strategies for delivering it to patients with type 1 diabetes. Topics will include identifying sites for the therapy, protecting the immune cells, and, once the cells are transplanted, monitoring the patient. Read more

Burnout has already contributed to a reduction in the workforce dedicated to caring for patients living with diabetes. Marie Brown, MD, of the American Medical Association will explain how to effectively address clinical burnout at an organizational level using real-world examples of success centered on practice efficiency. Read more

A panel of nephrology and diabetes experts, including Titilayo O. Ilori, MD, MSc, will discuss the impact of race, ethnicity, and underrepresentation of vulnerable populations in clinical trials in relation to diabetes and kidney disease. Read more

Scientific Sessions attendees in San Diego are invited to converse with Mandeep Bajaj, MBBS, editor of ADA’s partner journal BMJ Open, Diabetes Research & Care, and ADA’s President-elect of Medicine & Science; David A. D’Alessio, MD, editor of Diabetes; and Steve E. Kahn, MB, ChB, editor of Diabetes Care. Read more

A. Enrique Caballero, MD, advocates for thoughtfully designed diabetes education and prevention programs tailored to “speak to” the different audiences for which they are intended in order to optimize diabetes care and achieve better outcomes. He is the recipient of this year’s Outstanding Educator in Diabetes Award. Read more

Various self-assessment tools exist to help patients with diabetes monitor their daily activities and provide their care teams with insights into glucose levels. Methods for tracking behavioral markers include sleep monitoring and actigraphy devices to track physical activity. Soohyun Nam, PhD, APRN, ANP-BC, FAHA, FAAN, discussed ecological momentary assessments. Read more

Dietary choices are crucial for managing type 2 diabetes. Experts including Roy Taylor, MD, shared their perspectives on nutrition programs that have helped patients reduce or manage type 2 diabetes while also living healthier lives. These programs incorporate low-calorie diets, low-carb diets, and glycemic excursion minimization. Read more

Vanita R. Aroda, MD, will share results from two trials, OASIS 1 and PIONEER PLUS, and discuss the effectiveness of higher dose semaglutide in treating patients with type 2 diabetes as well as patients with obesity without type 2 diabetes. She will discuss how a high-dose semaglutide regimen can help patients reach their health goals. Read more

Raphael Scharfmann, PhD, will provide insight on the earliest beta cells: fetal pancreatic beta cells. His focus will be on the human fetal pancreas and what it can reveal about beta-cell identity. Other panelists will discuss postnatal beta cells and beta-cell aging. Read more

Two experts will present research on eliminating senescent cells that impact diabetes and aging-related metabolic disease. James L. Kirkland, MD, PhD, will discuss the use of senolytic drugs, and Anil Bhushan, PhD, will share his immunotherapy approach to eliminate senescent cells. Read more

A panel of diabetes and cardiovascular experts, including Jan Borén, MD, PhD, will discuss cardiovascular disease and people with diabetes. The symposium will cover contributing factors to cardiovascular residual risk, new drug targets, and methods to assess disease. Read more

As part of a panel in the ADA Diabetes Journal Symposium, Jonathan Z. Long, PhD, will discuss signaling pathways in energy metabolism, including exercise-induced mediators of body adiposity. He will also share cutting-edge research using a cell-type-specific proteomic approach. Read more

In recent years, telehealth technology has been more readily available and effective in connecting providers and patients. Jennifer Raymond, MD, MCR, will make the case for using telehealth in psychological care, while Michael A. Harris, PhD, will make the case for more research into telehealth models before wide adoption for this kind of care. Read more

Sarah C. Westen will explain what the Psychosocial Subcommittee of the Youth Strategies Committee has accomplished over the past two years. She will share videos created by the team as well as strategies to help improve communication between health care teams and children and their families. Read more

"Sip & Chat" with Alice Cheng, MD, FRCPC, and Michael Natter, MD, on Sunday in the Exhibit Hall. Dr. Cheng, co-host of the Diabetes Care “On Air” podcast and Scientific Sessions Meeting Planning Committee Chair, will interview Dr. Natter, a visual artist and endocrinologist, on how his artistic eye influenced his medical practice. Read more

As the 83rd Scientific Sessions got underway at the San Diego Convention Center, attendees gathered in the Exhibit Hall on Friday evening for a Networking Reception with exhibitors. In addition to providing an opportunity to engage with industry leaders, the event offered a preview of the Poster Hall and a venue to connect with friends and colleagues from across the country and around the world. Read more

Pathway to Stop Diabetes^® researchers, including Aleksandar D. Kostic, PhD, presented their new approaches for working toward a cure for this pervasive disease. These investigators are looking at the gut microbiome, cloaked beta-cells, branched-chain amino acid, dysregulation of the gut-brain axis by sugar, and diabetes distress with new perspectives with funding from the American Diabetes Association^®. Read more

Therapeutic inertia is a common problem in managing type 2 diabetes. Experts including Kevin M. Pantalone, DO, ECNU, FACE, addressed how it can be prevented, such as achieving A1C targets within a year of treatment, leveraging the entire health care team in the patient’s journey, and having accessibility to the patient’s electronic health record. Read more

New to the Scientific Sessions lineup, the Innovation Challenge invites six contestants to pitch their concepts for improving the lives of people living with diabetes before a panel of potential funders. Three finalists will earn a private audience with the judges, explained ADA Chief Scientific and Medical Officer Robert Gabbay, MD, PhD. Read more

A panel including Ellen Leschek, MD, will discuss teplizumab clinical trial results and the role of the CD3-directed monoclonal antibody in delaying the progression from stage 2 type 1 diabetes to stage 3. Joining Dr. Lesheck will be researchers, clinicians, and a patient with type 1 diabetes. Read more

Michael J. Haller, MD, and Antionette Moran, MD, will present data and arguments in support of technology and immunomodulation, respectively, in treating patients with type 1 diabetes. Dr. Haller said most experts likely agree there will be a role for both going forward and each should be discussed and offered to patients. Read more

Genome-wide association studies and polygenic risk scores are important tools in the field of genetics and have shown to also impact diabetes research. Experts including Inês Barroso, PhD, will present information on how GWAS and PRS have helped in the prevention, early diagnosis, and management of type 2 diabetes. Read more

For many years, rural residents in the United States were healthier as a population than their urban counterparts. In the 1980s, that began to change. Four researchers, including Vasan Ramachandran, MD, DM, FACC, FAHA, will discuss this trend in the context of diabetes diagnosis and care. Read more

Taking an innovative idea for diabetes care from the bench to the bedside requires funding. Presenters including Kathryn Zavala, PhD, COO and BioTools Innovator Managing Director, MedTech Innovator, will discuss what investors look for in a pitch. Read more

Some of the diabetes management tools with the greatest efficacy are those that patients can use by themselves. Experts including Sarah S. Jaser, PhD, will discuss the impact tracking blood glucose levels, sleep quality, diet choices, and other behaviors can have in disease management while paying tribute to behavioral diabetes pioneer Mark Peyrot, PhD. Read more

Proper nutrition can help regulate diabetes. Christopher Gardner, PhD, will discuss the advantages of consuming a plant-based, whole-food diet, along with the health and global benefits of switching from animal protein to plant-based protein. Other presenters will discuss portion size and calorie density, and how processed foods impact energy balance. Read more

The ADA’s Precision Medicine in Diabetes Initiative aims to tap into the potential of individualized medicine to improve the lives of people with diabetes. Genetic testing is one component of this strategy to better understand the disease and refine diagnostics. Rinki Murphy, MBChB, FRACP, PhD, and other experts will discuss why endotypes matter in achieving better diabetes outcomes. Read more

Managing foot care is a challenge people living with diabetes face on a daily basis. David G. Armstrong, DPM, MD, PhD, and other panelists will present approaches providers can implement to help their patients living with diabetes get ahead of foot injuries and improve foot health. Read more

Carrying extra weight exacerbates diabetes and can lead to a variety of metabolic and biomechanical complications. In SURMOUNT 2, a GLP-1/GIP dual receptor agonist led to weight loss in patients with both obesity and type 2 diabetes to an extent previously unseen. Investigators including W. Timothy Garvey, MD, will present trial results at the Scientific Sessions. Read more

Since the publication of the Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in 2021, the applicability of remission as a realistic treatment goal has evolved. A panel including Hertzel C. Gerstein, MD, MSc, FRCPC, will discuss the concept of remission in diabetes and its potential in research and patient care. Read more

Experts including Aimee Afable, PhD, MPH, will discuss the growing risk of diabetes in populations that immigrate to the U.S. and what may be leading to those risk factors. Discussions will include the challenges of adapting programs and approaches in treating and mitigating diabetes to meet the needs of culturally distinct communities. Read more

Last fall, the U.S. Food and Drug Administration approved teplizumab as the first disease-modifying therapy in type 1 diabetes. Experts including Stephen E. Gitelman, MD, will present insights from studies of teplizumab and other agents, including abatacept and hydroxychloroquine, that have provided road maps to help delay the onset of disease. Read more

People with diabetes are at risk for retinopathy. Ward Fickweiler, MD, will discuss research exploring the relationship between the presence of age-related macular degeneration and diabetic retinopathy severity in people with type 1 diabetes. Other panelists will discuss glucose management, prior cerebrovascular disease, and autonomous artificial intelligence diabetic eye exams. Read more

Panelists including Amit R. Majithia, MD, presented new opportunities and approaches to quantify and understand insulin resistance in diverse populations. Genome-wide association studies are among the tools that can tease out the genetic basis of metabolic responses. Read more

While current guidelines have limited data on the use of non-insulin therapies for patients with diabetes who are hospitalized, several randomized trials are focusing on the use of incretin-based therapy for this patient population, Smita Kumar, MD, explained at the 82nd Scientific Sessions. Read more

Patient fatigue with counting carbs and consuming high-protein snacks may drive interest in exploring dietary alternatives for type 2 diabetes management. Krista A. Varaday, PhD, discussed the effects of intermittent fasting and exercise on fasting insulin, insulin resistance, and insulin sensitivity, as well as the barriers to patient adherence to time-restricted eating. Read more

Loss of beta cell function happens abruptly around the time of type 1 diabetes onset, noted panelist Matthias von Herrath, MD, though many individuals with long-standing type 1 diabetes retain beta cell mass and some degree of beta cell function. Hallmarks of progression include upregulation of major histocompatibility complexes and the appearance of CD8-positive T-cells in islets. Read more

Among the available screening tools for type 1 diabetes, autoantibody testing can identify people who are in the early stages of the disease and are at high risk of developing clinical type 1 diabetes, providing a window of opportunity for early intervention and potentially preventing diabetic ketoacidosis, explained Chantal Mathieu, MD, PhD. Read more

Investigators found that three of the subphenotypes have increased glycemia, but only individuals in two clusters have imminent diabetes risks, explained Robert Wagner, MD. By contrast, they found another cluster of individuals with prediabetes who have only moderate risk of type 2 diabetes but an increased risk of kidney disease and all-cause mortality. Read more

Raja Kandaswamy, MD, reviewed indications and recent outcomes of pancreas transplant alone and simultaneous pancreas-kidney transplant in patients with type 1 and type 2 diabetes. Simultaneous transplants have excellent short- and long-term results, but long-term results of solitary pancreas transplants need to improve, he said. Read more

Little is known about the impact of low-calorie sweeteners on taste preferences, insulin secretion, adipogenesis, the gut microbiome, glucose absorption, and the risk of cardiometabolic disease, according to Michelle Pang, BSc. One reason for that is that they are structured differently but are often studied together, resulting in conflicting findings. Read more

An analysis of Diabetes Control and Complications Trial data, as well as a number of cross-sectional and longitudinal studies, provide evidence supporting the association between time in range and microvascular complications, cardiovascular disease, and mortality, according to Roy Beck, MD, PhD. Read more

Exercise management is trial and error and always will be as long as exogenous insulin is being manipulated, according to Laurel Messer, PhD, RN, CDCES, one of four experts who shared several clinical pearls in the practical use of automated insulin delivery systems. Read more

Insulin availability is a challenge across the globe, particularly in many lower- and middle-income countries. Panelists including Sylvia Kehlenbrink, MD, outlined the breadth of this obstacle to diabetes care and potential national and international strategies for overcoming it. Read more

To identify ways to help older adults increase their use of diabetes technology, several factors must be taken into consideration at each level of care, including systemic, clinician, personal caregiver, and patient factors. “The thing with technology is that you have the shoe, but it must fit for the right outcome,” said Medha Munshi, MD. Read more

Eda Cengiz, MD, MHS, who reviewed some of the most recent technological advances in diabetes care and management, said the most exciting development in this area has been automated insulin delivery, also known as artificial pancreas, hybrid closed-loop system, or bionic pancreas. Read more

Therapeutic inertia does not have a single cause. Clinician-, patient-, and systematic-related factors all contribute, said Christine Beebe, MS. Meta-analysis indicates that diabetes management programs should be set up to treat patients while taking into consideration different clinician types, clinic settings, and patient communications for optimal effectiveness. Read more

Expectant mothers who exercise have greater levels of docosahexaenoic acid (DHA) in late pregnancy than those who do not, explained Linda May, PhD, MS, FAHA. DHA helps mothers deliver on time, is good for placentas, helps control the mother’s lipids, and is essential for the baby’s growth and development. Read more

In a report to Congress earlier this year, the National Clinical Care Commission (NCCC) outlined more than three dozen recommendations for a national effort across multiple agencies and levels of government to address social determinants in the pathogenesis and progression of diabetes. NCCC Chair William H. Herman, MD, MPH, and other Commission members highlighted their recommendations at the 82nd Scientific Sessions. Read more

Carol H. Wysham, MD, says there is serious therapeutic inertia at play as patients often remain in poor glycemic control for more than seven years before intensification of treatment. Yet repeated studies show that up-titrating GLP-1 receptor agonist dosing improves glycemic outcomes as well as loss and maintenance of weight. Read more

Obesity can lead to insulin resistance, which sets the stage for the development of beta amyloid plaques and tau tangles in the brain, both hallmarks of Alzheimer’s disease. Some early trials of inhaled insulin in people with type 2 diabetes show improved memory, Auriel A. Willette, PhD, MS, and Vera Novak, MD, PhD, explained. Read more

An expert panel including Paul McGuigan, RN, CDCES, stressed that creating a continuum of care and support starting in high school, including promoting health insurance literacy, is key to setting up young people with type 2 diabetes to successfully manage their disease as they transition to adulthood. Read more

Afternoon training improves glucose sensitivity, increases fat loss, and increases work performance while reducing nocturnal blood glucose levels, said Juleen R. Zierath, PhD, one of the panelists discussing the molecular mechanisms known to affect the circadian rhythms of liver function. Read more

A distinguished panel of experts reviewed the latest information on the development of weekly insulins, oral insulins, glucose-sensitive insulin, and the role of biosimilars and interchangeable insulins on Monday, June 6. Michael A. Weiss, MD, PhD, MBA, discussed the development of glucose-sensitive insulin, or “smart insulin,” that can be activated through the use of a synthetic “switch” that can be opened or closed using a simple sugar sensor. Read more

Four weight loss researchers discussed the value of behavioral therapy, intensive lifestyle interventions, and pharmacotherapy during a Scientific Sessions symposium on Sunday, June 5. “There’s quite a bit of evidence showing that individuals who self-monitor over time generally are the best in terms of maintenance of behaviors and weight,” said Hollie Raynor, PhD, RD, LDN. Read more

An expert panel examined several barriers limiting the use of diabetes technology in under-resourced communities at the 82nd Scientific Sessions. “Regardless of their socioeconomic status, everyone deserves access to the right technology at the right time, especially in a chronic condition like diabetes,” said Vivian N. Ayuk, PharmD, CDCES. Read more

A panel of clinical leaders discussed the importance of educating hospital staff about diabetes management and care during a Scientific Sessions symposium on Monday, June 6. “It really does affect the patient experience when we don’t do an excellent job managing their glycemia, and that’s the point of education,” said Leigh B. Bak, MSN, APRN, ACNS-BC, CDCES. Read more

Racial, ethnic, and socioeconomic disparities that limit access to diabetes medications and technologies lead to poor glycemic control, diabetic emergencies, and adverse cardiovascular outcomes, according to Sara Jane Cromer, MD, one of three presenters in a symposium on Monday, June 6, that examined disparities in the use of diabetes medications and technologies. Read more

After SURMOUNT-1 trial results were reported at the Scientific Sessions on Saturday and made worldwide headlines, a special session on Tuesday, June 7, will showcase more than 20 tirzepatide abstracts presented over the five days of the meeting. “Attendees are seeing and hearing data that is being presented for the first time here in New Orleans,” said Katherine R. Tuttle, MD, FASN, FACP, FNKF, one of the session’s presenters. Read more

Genomic analysis, single-cell sequencing, and epigenomic approaches are uncovering new mechanisms in the development and progression of diabetic kidney disease. A panel of researchers, including Jose C. Florez, MD, PhD, will provide an update on the latest discoveries. Read more

Richard David Leslie, MBBS, MRCS, MD, FRCP, FAoP, says diabetes should be rethought. He will open a unique symposium on the final day of the 82nd Scientific Sessions that will examine various aspects of heterogeneity in diabetes. Read more

Three neurological researchers—Auriel Willette, PhD, Vera Novak, MD, PhD, and Valory Pavlik, PhD (left to right)—will discuss the links between diabetes and cognitive decline and explore possible interventions during a Scientific Sessions symposium on Tuesday, June, 7. Read more

Once thought of as nonfunctional vestigial relics of evolutionary history, cilia are emerging as critical components in multiple signaling pathways that control sight, smell, renal function, feeding behavior and obesity, skeletal formation, and, most recently, insulin secretion and glucose homeostasis. “Cilia biology is going to explode in diabetes,” predicts Jing Hughes, MD, PhD. Read more

Four researchers, including Dongyin Guan, PhD (left), Kristin Eckel-Mahan, PhD, will discuss how circadian misalignment impacts metabolic health during a Scientific Sessions symposium on Tuesday, June 7. Read more

Frances M. Ashcroft, DBE, FRS, FMedSci, recipient of the ADA’s 2022 Banting Medal for Scientific Achievement, discussed a novel approach—inhibiting glucokinase activity to improve insulin secretion—for treating type 2 diabetes during her award lecture on Sunday, June 5. Read more

Linda DiMeglio, MD, MPH, David A. D’Alessio, MD, and Silvia Corvera, MD (left to right), reviewed some of the key advances in diabetes research and care during the annual Year in Review session. Read more

Five behavioral health specialists discussed the effects of stigma in diabetes care during an afternoon symposium on Saturday, June 4. Alan M. Delamater, PhD, opened the symposium by recounting his 40-year journey in behavioral diabetes research as he presented the annual Richard R. Rubin Award Lecture. Read more

The recent emergence of effective anti-obesity medications raises the question of whether weight loss, rather than glucose control, should be considered the primary target for intervention in type 2 diabetes. Ildiko Lingvay, MD, MPH, MSCS, and Jeffrey I. Mechanick, MD, debated that question at the 82nd Scientific Sessions. Read more

Losing weight, no matter how much or how little, has health benefits for obese people with type 2 diabetes. And the more they lose, the better the outcome, said Priya Sumithran, PhD, one of three panelists in a Scientific Session symposium that explored the use of lifestyle interventions, bariatric surgery, and pharmacotherapy to manage obesity and type 2 diabetes. Read more

Research examining central nervous system control of systemic metabolism suggests that the CNS plays an important, and perhaps a dominant role in the pathogenesis and progression of at least some forms of diabetes. Four leaders in the field, including Vincent Prevot, PhD, and Sarah Stanley, MB, BCh, PhD, will review the latest findings at the Scientific Sessions. Read more

Cardiovascular disease is recognized as one of the most common complications of diabetes. Clinicians have long viewed coronary arterial disease and atherosclerosis as the major culprits, but heart failure has emerged as a larger problem—and one that’s more difficult to manage, according to Rong Tian, MD, PhD. Read more

Four cardiologists, including Yi Tan, PhD (left), and Harold E. Bays, MD, will discuss the underlying mechanisms, diagnosis, and treatment of cardiomyopathy, a familiar yet underappreciated complication of diabetes. “My sense is we are on the cusp of some really interesting times in cardiomyopathy in diabetes,” Dr. Bays said. Read more

Otis W. Kirksey, PharmD, RPh, CDCES, BC-ADM, ADA President, Health Care & Education, discussed his dedication to the diabetes community on Saturday, June 4, saying that improving the lives of people with diabetes takes equal parts of dedication and hard work. Read more

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, received the ADA’s 2022 Outstanding Educator in Diabetes Award at the 82nd Scientific Sessions. Diabetes self-management education and support (DSMES) should be the standard-of-care for every person with diabetes, she said. Read more

Davida F. Kruger, MSN, APN-BC, BC-ADM, told women at the Saturday afternoon symposium that if they’re not invited to the table, show up anyway—with a chair. And keep moving that chair closer and closer to the table. Read more

Physical activity is an integral part of the diabetes management toolbox, but not everyone responds to physical activity the same way or has the ability to exercise regularly. A panel of exercise scientists, including Carlos Crespo, PhD, examined how health disparities and sex differences impact physical activity during a morning symposium on Saturday, June 4. Read more

During an afternoon symposium on Friday, June 3, a diverse interprofessional panel of experts—including an epidemiologist, a health services researcher, a historian, and a medical anthropologist—shared their work and insights on the role of race and racism in diabetes research and diabetes care. “Implicit bias training alone does not work in terms of being sustainable. It has to be accompanied by systemic structural interventions—they go hand in hand,” said Marshall Chin, MD, MPH. Read more

Four experts, including Satish K. Garg, MD, and Holly Willis, PhD, RDN, CDCES, will discuss practical strategies to improve eating habits and optimize the growing number of insulin-dosing options to improve glucose control, increase time in range, reduce A1C, and lower the risk of long-term complications from poor glucose control. Read more

Jamie Feldman, MD, will chair a Scientific Sessions symposium examining diabetes, metabolic health, and clinical care among people who are lesbian, gay, bisexual, transgender, gender diverse, queer, or questioning. Read more

During a Friday afternoon session, an interprofessional panel of experts provided their perspectives and reviewed some of the most current literature on improving outcomes across the cardio-renal-metabolic spectrum of diabetes. “In the tsunami of diabetes, multidisciplinary, interdisciplinary therapy is essential if we are going to continue to improve outcomes,” said Neda Rasouli, MD. Read more

Alison Evert, MS, RDN, CDCES (left), and Maureen Chomko, RD, CDCES, addressed several nutrition controversies—from net carbs to fad diets to meal and snack frequency—during a mini-symposium on the first day of the 82nd Scientific Sessions. Read more

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES (left), and Michelle F. Magee, MD, MB, BCh, LRCPSI, will review the updated national standards for diabetes self-management education and support. A companion session will outline the revised certification program for certified diabetes care and education specialists. Read more

The ADA and the European Association for the Study of Diabetes published a consensus report on precision diabetes medicine in 2020. Scientific Sessions attendees will get an update on this joint initiative during a special symposium on Saturday, June 4. John M. Dennis, PhD (left), and David Kerr, MD, are two of the featured presenters. Read more